PETS
Petmed Express IncThe latest filing states the doubt was alleviated.
“The Company’s liquidity position at March 31, 2026 has been impacted by declining cash balances, declining net sales, recurring operating losses and for fiscal 2026, negative operating cash flows. When considered in the aggregate, these conditions raised substantial doubt about the Company's ability to continue as a going concern within the assessment period, defined as twelve months after the date that our consolidated financial statements are issued. Management evaluated the significance of these conditions in relation to the Company’s ability to meet its obligations within the assessment period and has developed a plan intended to alleviate substantial doubt. The primary elements of the plan include, among other things, advertising and media spend optimization, strategic reductions in operating expenses, including decreases in professional fees following the resolution of non-recurring matters, and reductions in capital expenditures. Management determined that these plans are probable of being effectively implemented and are probable of mitigating the conditions that raised substantial doubt and has concluded that substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following issuance of these consolidated financial statements has been alleviated.”View the 10-K filed Jun 2, 2026
Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$15.4M | Full Year Fiscal 2026 | — |
| Adjusted EBITDA loss non-GAAP | -$2.8M | Q4 FY2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Pharmaceutical Retailers — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PETS
this stock
Petmed Express Inc
|
$41.88M | -38.8% | -21.1% | — | 7.6% |
|
RTEZ
REST EZ Inc.
|
$1.93B | +0.0% | — | — | 0.0% |
|
WGRX
Wellgistics Health, Inc.
|
$385.81M | -84.7% | +0.0% | — | 0.1% |
|
HITI
High Tide Inc.
|
$192.79M | -16.6% | — | — | 0.8% |
|
BHIC
BioScience Health Innovations, Inc.
|
$49.58M | +8.6% | +208.3% | 144.8 | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PETS | -1.0% | +14.0% | -42.4% | +2.1% | -38.8% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -2.4% | +9.9% | -51.4% | +1.0% | -49.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.